Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Lupin Pharma
Lupin Pharma
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Aptar and Lupin to launch India’s first smart device for metered-dose inhalers
ADHERO is designed to help patients with chronic respiratory diseases track their MDI usage
Finance
Neopharma subsidiary buys Japanese injectables business
Indian pharma Lupin will also sell all related assets in Japan to Neo ALA
Lupin looks to compete with Sun Pharma in Japanese market
Wholly-owned Japanese subsidiary, Kyowa, intends to set up a manufacturing plant at Tottori, Japan, as part of expansion plans in the country
Regulatory
Indian pricing authority to address overcharging by pharma companies
NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Regulatory
Several large Indian pharma companies under US FDA scrutiny
Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Pharmaceutical
Lupin set to launch generic version of Valeant diabetes drug Glumetza
The Indian firm has a 180-day exclusivity for the product
Pharmaceutical
Indian generic manufacturers aim to enter the Japanese market
The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Subscribe now